Quarterly report · Q2
4554.TEDINET S100TDY6
Period2023-10-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥21.4bn | 2023-10-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥40.9bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥19.2bn | 2022-10-01 → 2023-03-31 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2023-10-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥1.8bn | 2022-10-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.2bn | 2023-10-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.5bn | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.5bn | 2022-10-01 → 2023-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥6.0bn | 2023-10-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.5bn | 2022-10-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.3bn | 2023-10-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.4bn | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.8bn | 2022-10-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥4.3bn | 2023-10-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥1.8bn | 2022-10-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥85.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥85.3bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥84.8bn | at 2023-03-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥40.9bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥44.2bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥44.1bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.2bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥40.5bn | at 2023-03-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.4bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥5.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2022-09-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥445m | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.9bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥1.5bn | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.2bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.9bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.0bn | 2023-10-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.9bn | 2022-10-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3.1bn | 2022-10-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥175.15 | 2023-10-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.43 | 2024-01-01 → 2024-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥141.37 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥72.95 | 2022-10-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.07 | 2023-01-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 51.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.7% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 488
| Item | Context | Value | Unit |
|---|---|---|---|
| Redemption of bonds fin cf | Prior1YTDDuration | － | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | -300000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -486000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -432000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -221000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -287000000 | JPY |
| Proceeds from sale and leaseback fin cf | Prior1YTDDuration | － | JPY |
| Proceeds from sale and leaseback fin cf | CurrentYTDDuration | 2331000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 3058000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -1998000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 33000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 37000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 1735000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -948000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3546000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2324000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 5282000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 1375000000 | JPY |
| Electronically recorded monetary claims discount | Prior1QuarterDuration | 1769000000 | JPY |
| Electronically recorded monetary claims discount | CurrentQuarterDuration | 1953000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 1368000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 1726000000 | JPY |
| Salaries and bonuses sga | Prior1YTDDuration | 1232000000 | JPY |
| Salaries and bonuses sga | CurrentYTDDuration | 1629000000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 307000000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 246000000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 89000000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 73000000 | JPY |
| Provision for directors bonuses sga | Prior1YTDDuration | 9000000 | JPY |
| Provision for directors bonuses sga | CurrentYTDDuration | 5000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-05-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第60期第２四半期(自 2024年１月１日 至 2024年３月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)富士製薬工業株式会社 | |
| Company name in english cover page | FilingDateInstant | Fuji Pharma Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 岩井 孝之 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都千代田区三番町５番地７ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)０３(３５５６)３３４４(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)執行役員 経営管理部長 宇治 浩 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都千代田区三番町５番地７ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)０３(３５５６)３３４４(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)執行役員 経営管理部長 宇治 浩 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00975 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45540 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)富士製薬工業株式会社 | |
| Filer name in english | FilingDateInstant | Fuji Pharma Co.,Ltd. |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |